DICLOVIX- diclofenac sodium, with camphor, lidocaine, and methyl salicylate patch kit

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

Drug Facts, Camphor 2%................Topical Analgesic, Lidocaine 2.5%............ Topical Analgesic, Methyl Salicylate 4%....Topical Analgesic, (NSAID: nonsteroidal anti-inflammatory drug)

Available from:

Primary Pharmaceuticals, Inc

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). Diclofenac sodium topical solution is contraindicated in patients with a known hypersensitivity to diclofenac sodium or any other component of diclofenac sodium topical solution. Diclofenac sodium topical solution is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.7, 5.10)]. Diclofenac sodium topical solution is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Warnings and Precaution

Product summary:

Diclofenac Sodium Topical Solution is supplied as a clear, colorless to faintly pink-orange solution containing 16.05 mg of diclofenac sodium per mL of solution, in a white high density polyethylene bottle with a white low-density dropper cap. NDC Number & Size 150 mL bottle NDC # 52565-002-05 Storage Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled RoomTemperature].

Authorization status:

Abbreviated New Drug Application

Patient Information leaflet

                                Primary Pharmaceuticals, Inc
----------
MEDICATION GUIDE FOR NON-STEROIDAL
ANTI-INFLAMMATORY DRUGS (NSAIDS)
(See the end of this Medication Guide for a list of prescription NSAID
medicines.)
What is the most important information I should know about medicines
called Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs)?
NSAID medicines may increase the chance of a heart attack or stroke
that can lead to death.
This chance increases:
•
with longer use of NSAID medicines
•
in people who have heart disease
NSAID medicines should never be used right before or after a heart
surgery called a "coronary artery
bypass graft (CABG)."
NSAID medicines can cause ulcers and bleeding in the stomach and
intestines at any time during
treatment. Ulcers and bleeding:
•
can happen without warning symptoms
•
may cause death
The chance of a person getting an ulcer or bleeding increases with:
•
taking medicines called "corticosteroids" and "anticoagulants"
•
longer use
•
smoking
•
drinking alcohol
•
older age
•
having poor health
NSAID medicines should only be used:
•
exactly as prescribed
•
at the lowest dose possible for your treatment
•
for the shortest time needed
What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?
NSAID medicines are used to treat pain and redness, swelling, and heat
(inflammation) from medical
conditions such as:
•
different types of arthritis
•
menstrual cramps and other types of short-term pain
Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?
Do not take an NSAID medicine:
•
if you had an asthma attack, hives, or other allergic reaction with
aspirin or any other NSAID
medicine
•
for pain right before or after heart bypass surgery
Tell your healthcare provider:
•
about all of your medical conditions.
•
about all of the medicines you take. NSAIDs and some other medicines
can interact with each
other and cause serious side effects. Keep a list of your medicines to
show to your healthcare
provider and pharmacist.
•
if you are pregnant, NSAID medicines should
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                DICLOVIX- DICLOFENAC SODIUM, WITH CAMPHOR, LIDOCAINE, AND METHYL
SALICYLATE PATCH
PRIMARY PHARMACEUTICALS, INC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
DICLOFENAC SODIUM TOPICAL SOLUTION SAFELY
AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DICLOFENAC
SODIUM TOPICAL SOLUTION.DICLOFENAC
SODIUM TOPICAL SOLUTION 1.5% W/W IS FOR TOPICAL USE ONLY.
INITIAL U.S. APPROVAL: 1988
WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISK
SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING
CARDIOVASCULAR RISK
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) MAY CAUSE AN INCREASED
RISK OF SERIOUS
CARDIOVASCULAR THROMBOTIC EVENTS, MYOCARDIAL INFARCTION, AND STROKE,
WHICH CAN BE FATAL. PATIENTS WITH
CARDIOVASCULAR DISEASE OR RISK FACTORS FOR CARDIOVASCULAR DISEASE MAY
BE AT GREATER RISK. ( 5.1)
DICLOFENAC SODIUM TOPICAL SOLUTION IS CONTRAINDICATED FOR THE
TREATMENT OF PERIOPERATIVE PAIN IN THE
SETTING OF CORONARY ARTERY BYPASS GRAFT (CABG) SURGERY. ( 4)
GASTROINTESTINAL RISK
NSAIDS, INCLUDING DICLOFENAC SODIUM TOPICAL SOLUTION CAUSE AN
INCREASED RISK OF SERIOUS
GASTROINTESTINAL ADVERSE EVENTS INCLUDING BLEEDING, ULCERATION, AND
PERFORATION OF THE STOMACH OR
INTESTINES, WHICH CAN BE FATAL. THESE EVENTS CAN OCCUR AT ANY TIME
DURING USE AND WITHOUT WARNING
SYMPTOMS. ELDERLY PATIENTS ARE AT GREATER RISK FOR SERIOUS
GASTROINTESTINAL EVENTS. ( 5.2)
RECENT MAJOR CHANGES
Dosage and Administration ( 2). . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . .
. . . . . . . . 10/2013
INDICATIONS AND USAGE
Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory
drug (NSAID) indicated for the treatment of signs
and symptoms of osteoarthritis of the knee(s). ( 1)
DOSAGE AND ADMINISTRATION
FOR THE RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS OF THE
KNEE(S), THE RECOMMENDED DOSE IS 40 DROPS ON
EACH PAINFUL KNEE, 4 TIMES A DAY. ( 2)
Apply diclofenac sodium topical solution to clean, dry skin. ( 
                                
                                Read the complete document